- Home
- CTMX vs BOWN Comparison
CTMX vs BOWN Comparison
Compare CTMX & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- BOWN
- Stock Information
- Founded
- CTMX 2008
- BOWN 2023
- Country
- CTMX United States
- BOWN United States
- Employees
- CTMX N/A
- BOWN N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- BOWN
- Sector
- CTMX Health Care
- BOWN
- Exchange
- CTMX Nasdaq
- BOWN Nasdaq
- Market Cap
- CTMX 444.3M
- BOWN 28.5M
- IPO Year
- CTMX 2015
- BOWN 2023
- Fundamental
- Price
- CTMX $2.42
- BOWN N/A
- Analyst Decision
- CTMX Strong Buy
- BOWN
- Analyst Count
- CTMX 2
- BOWN 0
- Target Price
- CTMX $5.00
- BOWN N/A
- AVG Volume (30 Days)
- CTMX 2.4M
- BOWN 2.7K
- Earning Date
- CTMX 08-07-2025
- BOWN 01-01-0001
- Dividend Yield
- CTMX N/A
- BOWN N/A
- EPS Growth
- CTMX 128.27
- BOWN N/A
- EPS
- CTMX 0.49
- BOWN 0.02
- Revenue
- CTMX $147,557,000.00
- BOWN N/A
- Revenue This Year
- CTMX N/A
- BOWN N/A
- Revenue Next Year
- CTMX N/A
- BOWN N/A
- P/E Ratio
- CTMX $5.36
- BOWN $206.51
- Revenue Growth
- CTMX 23.81
- BOWN N/A
- 52 Week Low
- CTMX $0.40
- BOWN $2.71
- 52 Week High
- CTMX $3.10
- BOWN $19.77
- Technical
- Relative Strength Index (RSI)
- CTMX 52.71
- BOWN 49.69
- Support Level
- CTMX $2.33
- BOWN $8.70
- Resistance Level
- CTMX $2.79
- BOWN $10.20
- Average True Range (ATR)
- CTMX 0.18
- BOWN 0.42
- MACD
- CTMX -0.01
- BOWN 0.04
- Stochastic Oscillator
- CTMX 46.38
- BOWN 79.04
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.